Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, nearly-stage classical Hodgkin lymphoma

Rákkutatás · Hodgkin lymphoma

The study demonstrates high efficacy and acceptable safety of the combination of brentuximab vedotin and nivolumab with doxorubicin and dacarbazine (AN+AD) in patients with early‑stage classical Hodgkin lymphoma.

Part of the source_content was not a traditional abstract, therefore the abstract field is omitted.

The trial indicates that adding novel immunotherapies to abbreviated chemotherapy can achieve near‑complete cure rates while potentially reducing treatment intensity and long‑term toxicity in early‑stage classical Hodgkin lymphoma.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek